Potential drug treats fatty liver disease in

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

Related Keywords

Michigan ,United States ,Peking ,Beijing ,China ,Jiaotong ,Guizhou ,Wayne State University ,Shanghai ,Yang Zhao ,Shanxi ,Zuowen Zheng ,Wanqing Liu ,Chao Xue ,Lemin Zheng ,Enqi Liu ,Liang Bai ,Rong Zeng ,Huiqing Wang ,Zhipeng Lui ,Sihai Zhao ,Wenbin Cao ,Mingming Zhao ,Jifeng Zhang ,Alexandrac Finney ,Shuangshuang Chen ,Xuelian Xiong ,Eugene Chen ,Ying Zhao ,Chengshuang Chu ,Duxin Sun ,Linying Jia ,Jinpeng Zhao ,Bo Wen ,Jiandie Lin ,Xiaojing Gao ,Shanghai Institute Of Biochemistry ,Xian Jiaotong University Health Science Center ,University Of Michigan ,Laboratory Animals ,Method Of Research ,Purdue University ,Spring Biological Technology Development Co ,Fudan University ,Louisiana State University Health Sciences Center ,Michigan Medicine ,Laboratory Animal Center ,Xi An Jiaotong University Health Science Center ,Cardiovascular Sciences ,Peking University Health Science Center ,Huetwell Professor ,Cardiovascular Medicine ,Michigan Medical ,Oren Rom ,Shusi Ding ,Beijing Tiantan Hospital ,Peking University ,Shanghai Institute ,Cell Biology ,Wayne State ,Institutional Animal Care ,Use Committee ,Laboratory Animal Care Committee ,Xi An Jiaotong University ,National Institutes ,Health Guide ,Nonalcoholic Steatohepatitis ,Non Human Primates ,